Vi capsular polysaccharide vaccine
|Trade names||Typherix, Typhim VI|
|AHFS/Drugs.com||Multum Consumer Information|
|(what is this?)|
The Vi capsular polysaccharide vaccine (or ViCPS) is one of two vaccines recommended by the World Health Organization for the prevention of typhoid (the other is Ty21a). The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine. A newer conjugate form of the vaccine (Vi bound to a non-toxic recombinant Pseudomonas aeruginosa exotoxin, or Vi-rEPA) has enhanced efficacy, including protection of children under 5 years of age.
The vaccine may be used in endemic areas in order to prevent typhoid. It is also commonly used to protect people who are traveling to parts of the world where typhoid is endemic.
The vaccine is injected either under the skin or into a muscle at least seven days before traveling to the typhoid-affected area (the CDC recommend 14 days). The vaccine is not effective in children under the age of two.
To maintain immunity, the vaccine should be repeated every three years.
Efficacy and duration of protection
The vaccine offers effective protection the first year after being given (with between 50% and 80% efficacy) and the second year (31% to 76%), but not after that.
- Lin, FY; Ho, VA; Khiem, HB; Trach, DD; Bay, PV; Thanh, TC; Kossaczka, Z; Bryla, DA; Shiloach, J; Robbins, JB; Schneerson, R; Szu, SC (26 April 2001). "The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children". The New England Journal of Medicine. 344 (17): 1263–9. doi:10.1056/nejm200104263441701. PMID 11320385.
- Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L (2007). "Vaccines for preventing typhoid fever". Cochrane Database Syst Rev (3): CD001261. doi:10.1002/14651858.CD001261.pub2. PMID 17636661.
|This vaccine article is a stub. You can help Wikipedia by expanding it.|